Corpus Intelligence IC Memo — TIMPANOGOS REGIONAL HOSPITAL 2026-04-26 09:55 UTC
IC Memo — TIMPANOGOS REGIONAL HOSPITAL
Investment Committee Memorandum | UT | 117 beds | Grade C | EBITDA uplift $11.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

TIMPANOGOS REGIONAL HOSPITAL

CCN 460052 | UTAH, UT | 117 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

TIMPANOGOS REGIONAL HOSPITAL is a 117-bed suburban community hospital in UTAH, UT with $156.1M in net patient revenue and a 38.3% operating margin. The hospital serves a payer mix of 8.2% Medicare, 9.0% Medicaid, and 82.9% commercial.

Thesis: Turnaround. Our ML models identify $11.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 38.3% to 45.7% (+736bps).

Net Revenue HCRIS$156.1M
Current EBITDA COMPUTED$59.8M
Operating Margin COMPUTED38.3%
Occupancy HCRIS43.0%
Revenue / Bed COMPUTED$1.3M
Net-to-Gross HCRIS26.3%
Distress Probability ML49.6%

2. Market Context & Competitive Position

59
UT Hospitals
8.0%
State Median Margin
15
Comparable Hospitals

UT has 59 Medicare-certified hospitals with a median operating margin of 8.0%. The target's margin of 38.3% places it above the state median. Among 15 size-comparable peers (58-234 beds), the median margin is 20.6%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (58-234), prioritizing same-state peers. 15 hospitals in the comp set.

HospitalStateBedsRevenueMargin
TIMPANOGOS REGIONAL HOSPITAL (Target)UT117$156.1M38.3%
LOGAN REGIONAL HOSPITALUT114$320.1M29.3%
LDS HOSPITALUT216$307.0M-5.5%
OGDEN REGIONAL MEDICAL CENTERUT174$299.3M47.4%
DAVIS HOSPITAL & MEDICAL CENTEUT175$235.1M29.1%
AMERICAN FORK HOSPITALUT88$216.8M25.3%
RIVERTON HOSPITALUT87$195.8M18.0%
LONE PEAK HOSPITALUT61$133.1M25.2%
AMEND #1 LAKEVIEW HOSPITALUT84$111.5M33.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $11.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$3.3M+210bp18mo
Cost to Collect4.5%2.5%$3.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$3.1M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.9M+122bp9mo
Clean Claim Rate88.0%96.0%$100K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$3.3M
Cost to Collect
$3.1M
Denial Rate Reduction
$3.1M
A/R Days Reduction
$1.9M
Clean Claim Rate
$100K
Total EBITDA Uplift$11.5M
Current EBITDA$59.8M
+ RCM Uplift+$11.5M
Pro Forma EBITDA$71.3M
Current Margin38.3%
Pro Forma Margin45.7%
WC Released (1x)$6.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$92.0M$509.6M5.54x40.8%
Base (11x exit)10.0x11.0x$92.0M$590.4M6.41x45.0%
Bull Case9.0x11.0x$82.8M$658.2M7.95x51.4%
Bull (12x exit)9.0x12.0x$82.8M$742.5M8.96x55.1%
Bear Case11.0x10.0x$101.3M$422.2M4.17x33.1%
Bear (11x exit)11.0x11.0x$101.3M$497.3M4.91x37.5%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 15 hospitals with 58-234 beds
  • Same-state prioritization (n=16)
  • Comp margins: P25=-5.6% / P50=20.6% / P75=29.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.